Predictive Oncology (NASDAQ:AGPU) Upgraded by Wall Street Zen to “Hold” Rating

Predictive Oncology (NASDAQ:AGPU) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

Separately, Weiss Ratings raised shares of Predictive Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Predictive Oncology Price Performance

AGPU stock opened at $7.16 on Monday. Predictive Oncology has a 12 month low of $1.03 and a 12 month high of $32.10. The business has a 50-day moving average of $6.39. The stock has a market cap of $77.47 million, a P/E ratio of -0.88 and a beta of 3.47.

Predictive Oncology (NASDAQ:AGPU) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million during the quarter. Predictive Oncology had a negative net margin of 470,383.31% and a negative return on equity of 7,363.67%.

About Predictive Oncology

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.